









Markets
/
Stocks
/
nasdaq-ogn
/

Organon & Co

OGN

6.100USD

-0.010-0.16%

Close 03/25, 16:00（ET）Quotes delayed by 15 min

1.54BMarket Cap

8.46P/E TTM



Organon & Co

6.100

-0.010-0.16%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Organon & Co

Currency: USD Updated: 2026-03-25

Key Insights

Organon & Co's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 85 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 8.67.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Organon & Co's Score

Industry at a Glance

Industry Ranking

85 / 157

Overall Ranking

230 / 4547

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Organon & Co Highlights

StrengthsRisks

Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 34.38%.

Overvalued

The company’s latest PE is 8.46, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 200.94M shares, decreasing 20.14% quarter-over-quarter.

Held by ETHSX

Star Investor ETHSX holds 5.39K shares of this stock.

Analyst Rating

Based on 9 analysts

Hold

Current Rating

8.667

Target Price

+42.31%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-25

The current financial score of Organon & Co is 7.91, ranking 79 out of 157 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 1.51B, representing a year-over-year decrease of 5.34%, while its net profit experienced a year-over-year decrease of 288.07%.

Score

Industry at a Glance

Previous score

7.91

Change



Financials

4.75

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.29

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.02

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

9.50

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Organon & Co's Company Valuation

Currency: USD Updated: 2026-03-25

The current valuation score of Organon & Co is 5.84, ranking 136 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is 8.46, which is 23.11% below the recent high of 10.42 and 72.40% above the recent low of 2.34.

Score

Industry at a Glance

Previous score

5.84

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 85/157

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-25

The current earnings forecast score of Organon & Co is 5.33, ranking 141 out of 157 in the Pharmaceuticals industry. The average price target is 9.00, with a high of 12.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

5.33

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 9 analysts

Hold

Current Rating

8.667

Target Price

+42.31%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

Organon & Co

OGN

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-25

The current price momentum score of Organon & Co is 6.60, ranking 109 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 7.14 and the support level at 5.41, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.62

Change

-0.02

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.010

Neutral

RSI(14)

30.014

Neutral

STOCH(KDJ)(9,3,3)

40.147

Buy

ATR(14)

0.225

High Vlolatility

CCI(14)

-85.660

Neutral

Williams %R

62.637

Sell

TRIX(12,20)

-0.939

Sell

StochRSI(14)

78.043

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

6.120

Sell

MA10

6.224

Sell

MA20

6.520

Sell

MA50

7.603

Sell

MA100

7.441

Sell

MA200

8.590

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-25

The current institutional shareholding score of Organon & Co is 7.00, ranking 42 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 77.29%, representing a quarter-over-quarter decrease of 8.62%. The largest institutional shareholder is The Vanguard, holding a total of 36.73M shares, representing 14.11% of shares outstanding, with 23.87% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

35.78M

+11.31%

BlackRock Institutional Trust Company, N.A.

27.75M

-1.87%

State Street Investment Management (US)

9.34M

-1.94%

AQR Capital Management, LLC

4.18M

+28.30%

LSV Asset Management

7.83M

-1.94%

MFS Investment Management

9.43M

-6.67%

Geode Capital Management, L.L.C.

4.82M

+9.55%

Private Management Group, Inc.

3.14M

+0.20%

UBS Financial Services, Inc.

2.73M

-53.87%

Risk Assessment

Currency: USD Updated: 2026-03-25

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Organon & Co is 4.81, ranking 82 out of 157 in the Pharmaceuticals industry. The company's beta value is 0.62. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.